Schedule of Events

4TH FLOOR FOYER
8:30 – 9:00 AM Registration

BALLROOM
9:00 - 9:15 AM Opening Remarks
9:15 – 11:15 AM 1st Slide Session
- Eric Deutsch, (9:15 - 9:45) Measuring Biomarkers of Friedreich Ataxia
- Michael Harbut, (9:45 - 10:15) A bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases
- Christopher Morgan, (10:15 - 10:45) Early prenatal stress disrupts masculinization of the mouse brain

11:15 – 11:45 PM Lunch
11:45 -1:00 PM Poster Session
1:00 - 2:30 PM 2nd Slide Session
- Michael Brewer, (1:00 – 1:30) SUMOylation and Tumorigenesis
- Robert Lin, (1:30 - 2:00) The relation of vasopressin in EEG and ultrasonic vocalizations pertaining to schizophrenia
- Jason Dunkelberger, (2:00 - 2:30) Characterization of cellular C5aR expression under resting and inflammatory conditions using a novel GFP knock-in mouse

2ND FLOOR FOYER
2:30 – 3:00 PM Coffee Break

3:00 – 4:00 PM The John S. O’Brien Memorial Lecture: Targeting alpha particles and nanotubes to cancer
- Dr. David Scheinberg Memorial Sloan Kettering Cancer Center (Translational targeted anti-cancer drugs and imaging agents)

4:00 - 4:15 PM Awards Ceremony

2ND FLOOR BOAT GALLERIES
Reception to follow
John S. O’Brien Memorial Lecture in Pharmacology

“Targeting Alpha Particles and Nanotubes to Cancer”

David Scheinberg was first introduced to the fields of medicine and science early in his life by his father, a physician-scientist, who allowed him to observe both experimental and clinical aspects of his career. David followed in his father’s footsteps and upon completion of college he enrolled in the MD-PhD program at The Johns Hopkins School of Medicine, where he completed his degree in Pharmacology and Experimental Therapeutics.

From 1992 to 2003 Dr. Scheinberg served as Chief of Memorial Sloan-Kettering Cancer Center’s Leukemia Service. He is currently the Vincent Astor Chair and Chairman, Molecular Pharmacology and Chemistry Program at the Sloan-Kettering Institute. In addition he founded and chairs the Experimental Therapeutics Center, and the Nanotechnology Center at Memorial Sloan-Kettering Cancer Center. He is a Professor of Medicine and Pharmacology and Co-chair of the Pharmacology graduate program at the Weill-Cornell University Medical College and Professor in the Gerstner-Sloan Kettering Graduate School and Memorial Sloan-Kettering Cancer Center.

Dr. Scheinberg’s research focuses on the discovery and development of novel, specific immuno-therapeutic agents for the purpose of cancer treatment. These include monoclonal antibodies that target the surface of cancerous cells, targeted radiopharmaceuticals that deliver radioactive particles including alpha particles or alpha particle nanogenerators, and targeted nano-devices for selective cell kill. In addition he investigates therapeutic vaccines targeting specific oncogene products.